Indian drugs giant Cipla said Friday it has slashed by up to 76 percent prices of generic medicines used to treat brain, lung and kidney cancer in what the company called a "humanitarian move".
May 4, 2012
0
0
(AP) -- A panel of advisers to the Food and Drug Administration voted Wednesday that the benefits of a Pfizer kidney cancer drug outweigh its risks, according to a company spokeswoman.
Dec 7, 2011
0
0
Treatment with three relatively new "targeted" cancer drugs has been linked to a slightly elevated chance of fatal side effects, according to a new analysis led by scientists at Dana-Farber Cancer Institute. They added that ...
Feb 6, 2012
0
0
(AP) -- India effectively ended Bayer's monopoly on a patented cancer drug Monday, licensing a much cheaper generic under a unique law aimed at keeping costs affordable.
Mar 12, 2012
0
1
German pharmaceutical giant Bayer AG has challenged a ground-breaking Indian ruling that allowed a local firm to produce a vastly cheaper copy of its patented drug for kidney and liver cancer.
May 6, 2012
0
0
India's patent appeals office has rejected Bayer AG's plea to stop the production of a cheaper generic version of a patented cancer drug in a ruling that health groups say is an important precedent for getting inexpensive ...
Mar 5, 2013
3
0
Biotech drugmaker Amgen is reportedly close to buying cancer drug maker Onyx Pharmaceuticals for about $10.5 billion.
Aug 25, 2013
0
0
(HealthDay)—U.S. Food and Drug Administration approval for the anti-cancer drug Nexavar (sorafenib) has been expanded to include late-stage differentiated thyroid cancer, the most common type of thyroid cancer.
Nov 24, 2013
0
0
Scientists for the first time have evidence showing how a widely used type of "targeted" cancer drug can be dangerous to the heart.
Nov 6, 2012
0
0
The kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay for nearly twice as long as a placebo, according to results of a randomized phase III trial, which will be presented today by a researcher ...
Jun 2, 2013
0
0
Sorafenib (co-developed and co-marketed by Bayer and Onyx Pharmaceuticals as Nexavar), is a drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma) and advanced primary liver cancer (hepatocellular carcinoma).
This text uses material from Wikipedia, licensed under CC BY-SA
